MXPA01010625A - Metodo para regulacion por disminucion de la actividad de interleucina 5. - Google Patents

Metodo para regulacion por disminucion de la actividad de interleucina 5.

Info

Publication number
MXPA01010625A
MXPA01010625A MXPA01010625A MXPA01010625A MXPA01010625A MX PA01010625 A MXPA01010625 A MX PA01010625A MX PA01010625 A MXPA01010625 A MX PA01010625A MX PA01010625 A MXPA01010625 A MX PA01010625A MX PA01010625 A MXPA01010625 A MX PA01010625A
Authority
MX
Mexico
Prior art keywords
regulating
activity
Prior art date
Application number
MXPA01010625A
Other languages
English (en)
Inventor
Steen Klysner
Original Assignee
Pharmexa As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa As filed Critical Pharmexa As
Publication of MXPA01010625A publication Critical patent/MXPA01010625A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5409—IL-5
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
MXPA01010625A 1999-04-23 2000-04-19 Metodo para regulacion por disminucion de la actividad de interleucina 5. MXPA01010625A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199900552 1999-04-23
US13281199P 1999-05-06 1999-05-06
PCT/DK2000/000205 WO2000065058A1 (en) 1999-04-23 2000-04-19 Method for down-regulating il5 activity

Publications (1)

Publication Number Publication Date
MXPA01010625A true MXPA01010625A (es) 2003-09-04

Family

ID=26064209

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01010625A MXPA01010625A (es) 1999-04-23 2000-04-19 Metodo para regulacion por disminucion de la actividad de interleucina 5.

Country Status (19)

Country Link
US (2) US7285273B1 (es)
EP (1) EP1173573A1 (es)
JP (1) JP2002543098A (es)
KR (1) KR20020084841A (es)
CN (1) CN1355846A (es)
AU (1) AU777952B2 (es)
CA (1) CA2370391A1 (es)
CZ (1) CZ20013709A3 (es)
EA (1) EA200101125A1 (es)
EE (1) EE200100552A (es)
HR (1) HRP20010824A2 (es)
HU (1) HUP0200958A3 (es)
IL (1) IL145786A0 (es)
MX (1) MXPA01010625A (es)
NO (1) NO20015021L (es)
PL (1) PL351986A1 (es)
SK (1) SK14832001A3 (es)
TR (1) TR200103046T2 (es)
WO (1) WO2000065058A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9706957D0 (en) 1997-04-05 1997-05-21 Smithkline Beecham Plc Formulation
GB9820525D0 (en) 1998-09-21 1998-11-11 Allergy Therapeutics Ltd Formulation
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
GB0000891D0 (en) 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7097837B2 (en) 2001-02-19 2006-08-29 Pharmexa A/S Synthetic vaccine agents
RU2319503C2 (ru) * 2001-11-07 2008-03-20 Цитос Байотекнолоджи Аг Композиция для иммунизации (варианты), способ ее получения и применение для лечения аллергических эозинофильных заболеваний
BR0213950A (pt) * 2001-11-07 2004-08-24 Cytos Biotechnology Ag Arranjos de antìgenos para o tratamento de doenças eosinofólicas alérgicas
EA007810B1 (ru) * 2001-11-16 2007-02-27 Фармекса А/С Иммуногенные миметики мультимерных белков с нерегулярными вставками т-клеточных эпитопов
AU2003260748A1 (en) * 2002-08-30 2004-03-19 Glaxo Group Limited Il-14 vaccine for the treatment of asthma and atopic disorders
JP2006503017A (ja) * 2002-08-30 2006-01-26 グラクソ　グループ　リミテッド Ｉｌ−１３要素及びｔ細胞エピトープを含む免疫原組成物並びにその治療上の使用
JP2007525436A (ja) * 2003-03-24 2007-09-06 マーシア・ファーマ・インコーポレイテッド 炎症症状を処置および予防するための方法および組成物
CN103091499B (zh) * 2013-01-23 2015-07-08 三峡大学 一种肿瘤标志物钙网蛋白检测试剂盒的制备及应用
RS57963B1 (sr) * 2013-02-22 2019-01-31 Regeneron Pharma Miševi koji eksprimiraju humanizovani glavni kompleks histokompatibilnosti
WO2014164640A1 (en) * 2013-03-11 2014-10-09 Regeneron Pharmaceuticals, Inc. Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules
CN113307870B (zh) * 2020-10-30 2022-12-23 上海洛启生物医药技术有限公司 抗il5纳米抗体及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096704A (en) 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
FR2677654B1 (fr) 1991-06-17 1995-11-17 Pasteur Merieux Serums Vacc Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv.
AU4377793A (en) 1992-05-20 1993-12-13 Johns Hopkins University, The Alternative receptor therapy
US5616488A (en) 1992-12-07 1997-04-01 Ribozyme Pharmaceuticals, Inc. IL-5 targeted ribozymes
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
AU698962B2 (en) 1993-09-14 1998-11-12 Epimmune, Inc. Alteration of immune response using pan DR-binding peptides
JPH09510975A (ja) 1994-03-28 1997-11-04 ユナイテッド・バイオメディカル・インコーポレイテッド アレルギー治療用合成ペプチドベース免疫原
AUPO005496A0 (en) 1996-05-24 1996-06-13 Bresagen Limited An interleukin-5 antagonist
ATE196297T1 (de) * 1994-05-18 2000-09-15 Synthetic Peptides Inc Heterodimere trägerzusammensetzung von immunogenen polypeptiden und verfahren zu deren verwendung
GB9412230D0 (en) * 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
WO1997000321A1 (en) 1995-06-14 1997-01-03 Commonwealth Scientific And Industrial Research Organisation Immune response modulators and uses therefor
CA2745736C (en) 1996-10-23 2016-11-22 The Trustees Of The University Of Pennsylvania Immunotherapy and improved vaccines
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
PT1005374E (pt) 1997-01-22 2007-07-18 Mgi Pharma Biolog Inc Micropartículas para administração de ácido nucleico
WO1998047923A1 (en) 1997-04-18 1998-10-29 Tanox Biosystems, Inc. Il-5r antagonists for treatment of inflammation, asthma and other allergic diseases
ES2222728T3 (es) * 1998-10-05 2005-02-01 Pharmexa A/S Procedimiento de vacunacion terapeutica.

Also Published As

Publication number Publication date
EE200100552A (et) 2002-12-16
SK14832001A3 (sk) 2003-02-04
CN1355846A (zh) 2002-06-26
WO2000065058A1 (en) 2000-11-02
AU4100800A (en) 2000-11-10
US7285273B1 (en) 2007-10-23
CZ20013709A3 (cs) 2002-11-13
HRP20010824A2 (en) 2002-12-31
NO20015021L (no) 2001-12-21
HUP0200958A2 (en) 2002-06-29
AU777952B2 (en) 2004-11-04
PL351986A1 (en) 2003-07-14
EP1173573A1 (en) 2002-01-23
HUP0200958A3 (en) 2004-11-29
NO20015021D0 (no) 2001-10-15
EA200101125A1 (ru) 2002-04-25
KR20020084841A (ko) 2002-11-11
US6746669B1 (en) 2004-06-08
TR200103046T2 (tr) 2002-06-21
JP2002543098A (ja) 2002-12-17
IL145786A0 (en) 2002-07-25
CA2370391A1 (en) 2000-11-02

Similar Documents

Publication Publication Date Title
ZA200109901B (en) Method for down-regulating GDF-8 activity.
HUP0104782A3 (en) Method for increasing pet activity
HUP0103578A3 (en) Method for down-regulating osteoprotegerin ligand activity
AU3850299A (en) Vegf activity inhibitors
ZA200001333B (en) Method for communicating information.
MXPA01010625A (es) Metodo para regulacion por disminucion de la actividad de interleucina 5.
EP1198306A4 (en) ENCLOSURE METHOD FOR PRESERVING BIO-RENOVABILITY
EP1304573A4 (en) METHOD FOR SCREENING A LIGAND WITH BIOLOGICAL ACTIVITY
GB2362530B (en) Method for improving the wireless location system
HUP0402231A3 (en) A method for determining the biological activity defibrotide
ZA200110053B (en) Factor via inhibitors.
GB0007871D0 (en) Method
GB9902302D0 (en) Detecting enzyume activity
AU6252901A (en) Methods for monitoring enzyme activity
GB2355455B (en) Method
GB0026109D0 (en) An analysis method
IL140058A0 (en) Methods for inhibiting tef-3 activity
GB2347213B (en) Method for determining nuclease activity
GB9921067D0 (en) Activity apparatus
SI1114166T1 (en) Method for down-regulating osteoprotegerin ligand activity
GC0000055A (en) Method for making dimethylnaphthalenes.
HU9902898D0 (en) Method for influancing thermosensibility
ZA994986B (en) Analysis system.
GB9917608D0 (en) Activity device
GB9922660D0 (en) Analysis method